Alzheimer's therapeutic development: shifting neurodegeneration to neuroregeneration

Miao-Kun Sun,Daniel L Alkon,Daniel L. Alkon
DOI: https://doi.org/10.1016/j.tips.2024.01.012
IF: 17.638
2024-03-08
Trends in Pharmacological Sciences
Abstract:Alzheimer's disease (AD), similar to AD-related dementias, is characterized by impaired/lost neuronal structures and functions due to a long progression of neurodegeneration. Derailed endogenous signal pathways and disease processes have critical roles in neurodegeneration and are pharmacological targets in inducing neuroregeneration. Pharmacologically switching/shifting the brain status from neurodegeneration to neuroregeneration is emerging as a new therapeutic concept, one that is not only achievable, but also essential for effective therapy for AD. The results of the pharmacological-induced shift from neurodegeneration to neuroregeneration are twofold: arresting cognitive deterioration (and directing the brain toward cognitive recovery) in established AD, and preventing neurodegeneration through building up cognitive resilience in patients with preclinical or probable AD. In this review, we discuss these new developments in AD pharmacology and relevant clinical trials.
pharmacology & pharmacy
What problem does this paper attempt to address?